Lung Cancer

Cancer Survivors Face Hardship Over Medical Bills

Cancer Survivors Face Hardship Over Medical Bills

Hardships are greatest in younger cancer survivors vs patients without cancer history.

Stage 4 ALK-Positive NSCLC Survival Is Nearly 7 Years

Stage 4 ALK-Positive NSCLC Survival Is Nearly 7 Years

Most patients in the study received crizotinib; prognosis worse when more organs had tumors at diagnosis.

Malignant Pleural Effusion Interventions: What Matters Most to the Patient?

Malignant Pleural Effusion Interventions: What Matters Most to the Patient?

By

Patients with malignant pleural effusion may care more about relieving symptoms such as dyspnea as opposed to achieving pleurodesis.

Suicide Risk Increased in Year After Cancer Diagnosis

Suicide Risk Increased in Year After Cancer Diagnosis

Higher suicide rates observed for cancers with poor prognosis, including pancreatic and lung cancer.

Arterial Thromboembolic Event Risk Increased Prior to Cancer Diagnosis

Arterial Thromboembolic Event Risk Increased Prior to Cancer Diagnosis

In seniors, risk for arterial thromboembolic events peaked in the 30 days immediately before cancer diagnosis.

Lung Cancer Risk Elevated in Lung Transplant Recipients

Lung Cancer Risk Elevated in Lung Transplant Recipients

A 13-fold increased risk was found in native lung for those receiving single lung transplant.

Exercise Linked to Reduced Mortality in Patients With Cancer

Exercise Linked to Reduced Mortality in Patients With Cancer

Mortality rate was lower for habitually active patients and for those who started exercising after their cancer diagnosis.

Atezolizumab/Bevacizumab Combination Approved for Metastatic Non-Squamous NSCLC

Atezolizumab/Bevacizumab Combination Approved for Metastatic Non-Squamous NSCLC

By

The approval was based on data from the IMpower 150 trial, an open-label study involving 1202 patients with stage IV metastatic NSq NSCLC who had not received prior chemotherapy for metastatic disease, but could have received prior EGFR or ALK kinase inhibitor if appropriate, regardless of PD-L1 or T-effector gene status and ECOG performance status 0 or 1.

Thirdhand Smoke: A New Concept Rising From Old Residue

Thirdhand Smoke: A New Concept Rising From Old Residue

By

The concept of thirdhand smoke was originally introduced in 1953, when rodent studies first demonstrated the carcinogenic effects of the residue from tobacco smoke.

Lung Cancer Screening Implementation Guide Developed

Lung Cancer Screening Implementation Guide Developed

The implementation guide is designed to increase levels of lung cancer screening in heavy smokers.

Cancer Pain Severity May Be Reduced With Smartphone-Based App

Cancer Pain Severity May Be Reduced With Smartphone-Based App

The smartphone-based app can cut both the severity of advanced cancer patients' reported pain and hospital admissions.

Coordinated Care Needed for Cancer Survivors, Caregivers

Coordinated Care Needed for Cancer Survivors, Caregivers

There is an urgent need for coordinated, comprehensive, personalized care for cancer survivors and caregivers.

Cough in Lung Cancer Associated With Gastrointestinal Symptoms

Cough in Lung Cancer Associated With Gastrointestinal Symptoms

By

The median duration of reported cough at study entry was 52 weeks and it was severe enough in more than half of participants that it warranted treatment.

Thoracotomy, Adjuvant Therapy Increase Risk for Opioid Use After Lung Resection

Thoracotomy, Adjuvant Therapy Increase Risk for Opioid Use After Lung Resection

By

Being 64 years or younger, being male, having underwent a thoracotomy, and using adjuvant therapy were all associated with a greater risk for persistent opioid use.

After NSCLC Resection, No Benefit to More Frequent Surveillance

After NSCLC Resection, No Benefit to More Frequent Surveillance

More frequent postsurgical surveillance is not associated with improved survival in non-small cell lung cancer.

Lung Cancer Mortality Predicted to Drop by 79%

Lung Cancer Mortality Predicted to Drop by 79%

Annual number of deaths from lung cancer are expected to continue to decrease despite the growth and aging of the US population.

Lorlatinib Approved for Previously-Treated ALK-Positive Metastatic NSCLC

Lorlatinib Approved for Previously-Treated ALK-Positive Metastatic NSCLC

By

The FDA has approved Lorbrena (lorlatinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC.

Pembrolizumab Combination Approved for First-Line Metastatic Squamous NSCLC Treatment

Pembrolizumab Combination Approved for First-Line Metastatic Squamous NSCLC Treatment

By

The FDA has approved Keytruda in combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-line treatment of patients with metastatic squamous NSCLC.

Durvalumab Extends Survival in Stage 3 Non-Small Cell Lung Cancer

Durvalumab Extends Survival in Stage 3 Non-Small Cell Lung Cancer

Both overall and progression-free survival were longer with durvalumab vs placebo.

Commonly Prescribed Antihypertensives Linked to Increased Lung Cancer Risk

Commonly Prescribed Antihypertensives Linked to Increased Lung Cancer Risk

By

To investigate the association between this commonly used antihypertensive class and lung cancer, researchers conducted a population based cohort study involving 992,061 patients from the United Kingdom Clinical Practice Research Datalink.

Open Surgery for Early Lung Cancer Tied to Long-Term Opioid Use

Open Surgery for Early Lung Cancer Tied to Long-Term Opioid Use

Patients who had video-assisted thoracoscopic surgery were less likely to use opioids long term.

Tobacco Use Remains Leading Modifiable Cause of Cancer

Tobacco Use Remains Leading Modifiable Cause of Cancer

Tobacco control could prevent more cancer deaths than any other strategy.

Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer

Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer

By

Significant improvements were seen with the addition of atezolizumab to CnP in stage IV non-squamous non-small cell lung cancer, regardless of patient PD-L1 status.

Metastatic NSCLC Treatment Aided by Plasma-Based Genotyping

Metastatic NSCLC Treatment Aided by Plasma-Based Genotyping

Most patients with metastatic non-small cell lung cancer who received targeted therapy based on plasma result achieved clinical response.

Lung Cancer Deaths 28% Lower in California Than Rest of US

Lung Cancer Deaths 28% Lower in California Than Rest of US

In individuals aged 18 to 35, California has had larger drops in smoking initiation, intensity, and higher rates of quitting.

Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC

Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC

By

Researchers investigated whether the rates of immune-related adverse events linked to treatment with nivolumab or pembrolizumab were similar across 2 different cancer types.

Longer Survival in NSCLC With Brigatinib vs Crizotinib

Longer Survival in NSCLC With Brigatinib vs Crizotinib

Longer progression-free survival was significantly longer in patients with ALK-positive disease who did not previously take an ALK inhibitor.

Integrated Classifier Identifies Benign Lung Nodules

Integrated Classifier Identifies Benign Lung Nodules

Classifier integrates relative abundance of 2 plasma proteins with clinical risk prediction model for lung nodules.

Vizimpro Approved as First-Line Treatment for EGFR-Mutated Metastatic NSCLC

Vizimpro Approved as First-Line Treatment for EGFR-Mutated Metastatic NSCLC

By

The approval was based on data from the ARCHER 1050 open-label, active controlled study which randomized patients with unresectable, metastatic NSCLC to treatment with either dacomitinib (N=227) or gefitinib (N=225).

Salvage Therapy for Recurrent SABR-Treated Early-Stage NSCLC Increases Survival

Salvage Therapy for Recurrent SABR-Treated Early-Stage NSCLC Increases Survival

By

Salvage treatment for recurrence of early-stage non-small cell lung cancer after initial treatment with stereotactic ablative radiotherapy improved patient survival.

Sign Up for Free e-newsletters